Clinical trials: Balanced
Healthy
Mass Balance Study of [14C]-NT-814 Oral Suspension in Healthy Male Subjects
This is a single centre, open-label, non-randomised study to assess the mass balance recovery, absorption, metabolism, and excretion of a single oral dose of [14C]-NT-814 in healthy male subjects.
- Trial name
- NCT04654897
- Testing
- [14C]-NT-814
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib
This is a single-center, open label and single-dose clinical trail, to explore the body mass balance and identify the major metabolites in Chinese adult male healthy volunteers after a single oral dose of [14C]Sulfatinib, to…
- Trial name
- NCT03627520
- Testing
- [14C]Sulfatinib
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hutchison Medipharma Limited
ER-positive, HER2-negative Breast Cancer
A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833
The Sponsor is developing the test medicine, AZD9833 for the potential treatment of estrogen receptor (ER)-positive breast cancer.
- Trial name
- NCT05364255
- Testing
- [14C]AZD9833 Oral Solution, 75 mg
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer's Disease
Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects
To evaluate the effects of a high-calorie high-fat meal on the extent and rate of absorption of CHF 5074 after single oral administration in young healthy male volunteers.
- Trial name
- CT03 (NCT01258452)
- Testing
- CHF 5074, CHF 5974
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- CERESPIR
Bioequivalence, Diabetes Mellitus, Type 2
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.
The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose…
- Trial name
- NCT06124547
- Testing
- Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet
- Where
- Mexico
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Galenicum Health
Healthy
Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C] LC15-0444
This was an open-label, non-randomised, single-dose study in 6 healthy male subjects. Subjects attended a screening visit within 28 days before drug administration.
- Trial name
- NCT01603238
- Testing
- [14C]-LC15-0444
- Where
- South Korea
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Epilepsy
Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects
Primary Objectives: To determine the excretion balance and systemic exposure of radioactivity after oral administration of [14C]-sodium valproate (VPA) .
- Trial name
- NCT03681158
- Testing
- sodium valproate
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy
A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)
The purpose of this study is to learn what happens to enlicitide chloride labeled with [¹⁴C] in a person's body over time. A label can be added to a study medicine to trace it in a person's body.
- Trial name
- NCT06658626
- Testing
- [¹⁴C]Enlicitide chloride
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Antifungal Agents
Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions
Griseofulvin is an antifungal agent used in treatment of Dermatophytosis caused by Microsporum spp. (species), Trichophyton spp., Epidermophyton spp., where topical therapy is considered inappropriate or has failed.
- Trial name
- NCT04318535
- Testing
- Griseofulvin 500 mg, Griseofulvin 250 mg, Reference Griseofulvin 500 mg
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteer
Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961
This study is a Phase 1, open-label, non-randomized, 2-period, fixed sequence study to characterize the metabolic profile and routes of excretion of oral [14C]PF-06882961 and to evaluate the absolute oral bioavailability of…
- Trial name
- NCT04495140
- Testing
- [14C]PF-06882961, 50 mg, PF-06882961, 50 mg and [14C]PF-06882961, 100 ug
- Where
- 2 sites in Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteer
Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948
This is a Phase 1, 2-period, open-label, single-dose, fixed-sequence study to assess the absolute bioavailability, absorption, metabolism, excretion, and mass balance of [14C]-NX-5948.
- Trial name
- NCT06691828
- Testing
- NX-5948
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Nurix Therapeutics, Inc.
Healthy Volunteers
A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants
The purpose of this study is to determine: Period 1 (ABA): ABA of mobocertinib following single microdose intravenous administration of 50 microgram (mcg) (approximately 2 microcurie [mcCi]) [14 C]-]-mobocertinib and single oral…
- Trial name
- NCT03811834
- Testing
- Mobocertinib
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Healthy Subjects
A Study in Healthy Volunteers to Investigate How Much Test Medicine [14C]-Uproleselan is Taken up by the Body When Administered Directly Into the Vein (IV)
The purpose of the study is to measure how the radiolabelled test medicine [14C]-Uproleselan (GMI-1271) is taken up, broken down and removed from the body when given intravenously (into a vein) in a group of 6 males.
- Trial name
- NCT03606447
- Testing
- Uproleselan
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- GlycoMimetics Incorporated
Healthy
Mass Balance Study of [14C]HSK31858 in Healthy Adult Male Chinese Subjects.
This is a single-center, nonrandomized, and open design study to investigate the pharmacokinetics, mass balance, metabolism and excretion of HSK31858 in healthy male subjects.
- Trial name
- NCT06569784
- Testing
- [14C]HSK31858
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Xizang Haisco Pharmaceutical Co., Ltd
Psoriasis
HPP737 Substance Balance Study in Human
Main research purpose 1. Quantitative analysis of the total amount of radioactivity in excreta (urine and feces) of male healthy subjects after oral administration of [14C]HPP737, to obtain the cumulative excretion rate and main…
- Trial name
- NCT06584058
- Testing
- HPP737
- Where
- China
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Newsoara Biopharma Co., Ltd.
Healthy
Excretion Balance of 14c-radiolabeled BIRB 796 BS in Normal Male Subjects
Study to characterize the pharmacokinetics of 14C-radiolabeled BIRB 796 BS and its metabolites including excretion and mass balance of parent compound and radioactivity; to isolate, identify and quantify major radiolabeled…
- Trial name
- NCT02211885
- Testing
- 14C-BIRB 796 BS
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
[14C] Mass Balance Clinical Trial of Azvudine in Healthy Male Subjects
Azvudine(FNC)，a nucleoside reverse transcriptase inhibitor, make itself a better candidate to be co-formulated in other anti-HIV therapies, thus to improve patient's compliance.
- Trial name
- NCT07002281
- Testing
- [14C]Azvudine suspension
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Henan Genuine Biotech Co., Ltd.
Vaginal Health, Bacterial Vaginosis
A Single Group Study to Evaluate the Effects of a Boric Acid Suppository on Vaginal Health.
This is a virtual single-group clinical trial that will last 12 weeks. Participants will use The Killer® (Boric Acid Suppositories) once daily for 7 consecutive days when they feel that they are experiencing any of the common…
- Trial name
- NCT06516757
- Testing
- Boric Acid Suppository
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Love Wellness
Hypogonadism
Efficacy of an Intranasal Testosterone Product
This clinical trial will compare the pharmacokinetic profile of testosterone after repeated intranasal administration of TBS-1 of different strengths in subjects with hypogonadism
- Trial name
- NCT01252745
- Testing
- 10.0 mg of Testosterone, 4.0% TID, 13.5 mg of Testosterone, 4.5% B.I.D, 11.25 mg of Testosterone, 4.5% T.I.D
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Acerus Pharmaceuticals Corporation
Healthy Male Subjects
Mass Balance Study of TS-142 in Healthy Adult Subjects.
To assess the plasma pharmacokinetics, the routes extent of elimination, and the metabolites of TS-142 after single oral dose of [14C] TS-142 in Japanese healthy male subjects.
- Trial name
- NCT04814771
- Testing
- [14C] TS-142
- Where
- Japan
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Taisho Pharmaceutical Co., Ltd.